You are here

Sanofi

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

BioSpace

Flag link:

As digital medicine explodes in the zeitgeist of healthcare, Sanofi follows peers in appointing chief digital officer

As digital medicine explodes in the zeitgeist of healthcare, Sanofi follows peers in appointing chief digital officer

Endpoints

digital medicine

chief technology officers

Flag link:

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Biopharma Dive

PCSK9 inhibitors

Flag link:

Pharma companies clear the R&D decks in Q4

Pharma companies clear the R&D decks in Q4

Pharmaforum

Gilead Sciences

Flag link:

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

Endpoints

Flag link:

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

BioSpace

Flag link:

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

Yahoo/Zacks.com

Flag link:

FDA approves Sanofi's Cablivi for rare clotting disease

FDA approves Sanofi's Cablivi for rare clotting disease

BioCentury

Flag link:

CEOs of Pfizer, Merck, Sanofi to testify in Senate drug pricing hearing

CEOs of Pfizer, Merck, Sanofi to testify in Senate drug pricing hearing

Biopharma Dive

Flag link:

Cancer-Vaccine Maker BioNTech Considering an IPO in U.S.

Cancer-Vaccine Maker BioNTech Considering an IPO in U.S.

Yahoo/Bloomberg

cancer vaccines

Flag link:

Powerful Senate committee invites pharma executives to testify

Powerful Senate committee invites pharma executives to testify

Reuters

Bristol-Myers Squibb

Flag link:

Sanofi's isatuximab meets survival endpoint for third-line multiple myeloma

Sanofi's isatuximab meets survival endpoint for third-line multiple myeloma

BioCentury

relapsed or refractory multiple myeloma

Multiple Myeloma

Flag link:

Sanofi Raises Public Health Questions on Use of Nonsense Suffixes With New Vaccines

Sanofi Raises Public Health Questions on Use of Nonsense Suffixes With New Vaccines

RAPS.org

Flag link:

On heels of drug pricing hearings, Democratic lawmakers kick off insulin probe

On heels of drug pricing hearings, Democratic lawmakers kick off insulin probe

Fierce Pharma

Flag link:

FDA advisers divided on Sanofi’s oral type 1 diabetes drug

FDA advisers divided on Sanofi’s oral type 1 diabetes drug

Pharmaforum

Lexicon Pharmaceuticals

type 1 diabetes

advisory panels

Flag link:

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi expands multitargeting toolbox with Biomunex deal

BioCentury

Biomunex Pharmaceuticals

drug development

Flag link:

Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma

Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma

BioSpace

SAGE Therapeutics

Bristol-Myers Squibb

Gilead Sciences

Flag link:

JPM: Years into troubled launch, vaccine head says Sanofi's learned some Dengvaxia lessons

JPM: Years into troubled launch, vaccine head says Sanofi's learned some Dengvaxia lessons

Fierce Pharma

Flag link:

Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact

Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact

Fierce Biotech

immuno-oncology

Flag link:

After Pfizer, Sanofi becomes partner of German biotech BioNTech

After Pfizer, Sanofi becomes partner of German biotech BioNTech

GoinPharma

Flag link:

Pages